Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 7:45 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | 110K | n/a |
Gross Profit | -110K | n/a |
Operating Income | -31.29M | -27.91M |
Interest Income | 2.7M | 1.13M |
Pretax Income | -28.94M | -26.87M |
Net Income | -28.94M | -26.87M |
Selling & General & Admin | 6.45M | 5.02M |
Research & Development | 24.73M | 22.89M |
Other Expenses | n/a | n/a |
Operating Expenses | 31.18M | 27.91M |
Interest Expense | 272K | 98K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 31.29M | 27.91M |
Income Tax Expense | n/a | n/a |
Shares Outstanding (Basic) | 44.33M | 41.81M |
Shares Outstanding (Diluted) | 44.33M | 41.81M |
EPS (Basic) | -0.65 | -0.64 |
EPS (Diluted) | -0.65 | -0.64 |
EBITDA | -31.18M | -26.71M |
EBIT | -31.29M | -26.77M |
Depreciation & Amortization | 110K | 63K |
Add to Watchlist
Select watchlists to add or remove AVLN